

---

National Institute for Health and Clinical Excellence

**Bevacizumab in combination with capecitabine for the first-line  
treatment of metastatic breast cancer [ID54]**

---

Royal College of Nursing

---

## **Introduction**

The Royal College of Nursing (RCN) was invited to review the Appraisal Consultation Document (ACD) for Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer.

Nurses caring for people with breast cancer reviewed the documents on behalf of the RCN.

## **Appraisal Consultation Document – RCN Response**

The Royal College of Nursing welcomes the opportunity to review this document. The RCN's response to the four questions on which comments were requested is set out below:

i) **Has the relevant evidence has been taken into account?**

The evidence considered seems comprehensive.

ii) **Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?**

We would ask that the summaries of the clinical and cost effectiveness of this appraisal should be aligned to the clinical pathway followed by patients with metastatic breast cancer. The preliminary views on

resource impact and implications should be in line with established standard clinical practice.

iii) **Are the provisional recommendations sound and a suitable basis for guidance to the NHS?**

Nurses working in this area of health have reviewed the recommendations of the Appraisal Committee and do not have any other comments to add.

The RCN would welcome guidance to the NHS on the use of this health technology.

iv) **Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of gender, race, disability, age, sexual orientation, religion or belief?**

None that we are aware of.

v) **Are there any equality-related issues that need special consideration that are not covered in the appraisal consultation document?**

We are not aware of any specific issue at this stage. We would ask that any guidance issued should show that an equality impact analysis has been considered and that the guidance demonstrates an understanding of issues relating to all the protected characteristics where appropriate.